Anthracycline-resistant breast cancer

Breast Cancer

Volumn 4, Issue 4, 1997, Pages 221-227

  Hortobagyi, Gabriel N ^a   Pivot, Xavier ^a   Asmar, Lina ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Anthracycline resistant; Breast cancer; Chemotherapy

Indexed keywords

EID: 84858055349     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966510     Document Type: Conference Paper

References (40)

1. Hortobagyi GN: Endocrine treatment of breast cancer. In: Becker KL ed, Principles and Practice of Endocrinology and Metabolism, 2nd ed, J.B. Lippincott Company, Philadelphia, pp1868-1875, 1995.
2. Henderson IC: Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW eds, Breast Diseases, 2nd ed, J.B. Lippincott Company, Philadelphia, pp604-665, 1991.
3. Tormey DC, Gray R, Abeloff MD, et al: Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients; An Eastern Cooperative Oncology Group Trial. J Clin Oncol 10(12):1848-1856, 1992. (Pubitemid 23064195)
4. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/-MER) for metastatic carcinoma of the breast; A CALGB study; Cancer and Leukemia Group B. J Clin Oncol 5(10):1523-1533, 1987. (Pubitemid 18010128)
5. Bull JM, Tormey DC, Li SH, et al: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41(5):1649-1657, 1978. (Pubitemid 8335369)
6. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer; The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67(4):801-805, 1993. (Pubitemid 23101563)
7. Greenberg PA, Hortobagyi GN, Smith TL, et al: Longterm follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14(8):2197-2205, 1996. (Pubitemid 26264869)
8. Swenerton KD, Legha SS, Smith T, et al: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552-1562, 1979. (Pubitemid 9172673)
9. Hortobagyi GN, Smith TL, Legha SS, et al: Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1:776-786, 1983. (Pubitemid 14167252)
10. Pivot X, Asmar L, Hortobagyi GN, et al: A unified definition of clinical anthracycline resistant breast cancer [Abstract]. Proc Am Soc Clin Oncol 16:146a (Abst 512), 1997.
11. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10(1):117-127, 1992.
12. Hortobagyi GN, Frye D, Buzdar AU, et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63(1):37-45, 1989. (Pubitemid 19031978)
13. Hortobagyi GN: Overview of new treatments for breast cancer. Breast Cancer Res Treat 21:3-13, 1992.
14. Booser D J, Hortobagyi GN: Anthracycline antibiotics in cancer therapy; Focus on drug resistance [Review]. Drugs 47(2):223-258, 1994.
15. Jones S, Winer E, Vogel C, et al: A multicenter, randomized trial of IV navelbine vs. IV alkeran in patients with anthracycline-refractory advanced breast cancer [Abstract]. Proc Am Soc Clin Oncol 13:103 (Abst 216), 1994.
16. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracyclinerefractory advanced breast cancer. J Clin Oncol 13(10)2567-2574, 1995.
17. Pazdur R, Kudelka AP, Kavanagh J J, et al: The taxoids; Paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19:351-386, 1993. (Pubitemid 23333409)
18. Verweij J, Clavel M, Chevallier B: Paclitaxel (Taxol) and docetaxel (Taxotere); Not simply two of a kind. Ann Oncol 5:495-505, 1994.
19. Hortobagyi GN, Holmes FA, Theriault RL, et al: Use of Taxol (paclitaxel) in breast cancer. Oncology 51(Suppl 1):29-32, 1994. (Pubitemid 24344636)
20. Seidman AD, Hudis CA, Norton L: Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer; From advanced disease to adjuvant therapy. Sernin Oncol 22(4, Suppl 8): 3-8, 1995.
21. Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1(2):247-256, 1995.
22. Seidman AD, Reichman BS, Crown JP, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer; Activity independent of prior anthracycline response. J Clin Oncol 13(5):1152-1159, 1995.
23. Buzdar AU, Holmes FA, Hortobagyi GN: Paclitaxel in the treatment of metastatic breast cancer; M. D. Anderson Cancer Center experience [Review]. Semin Oncol 22(3, Suppl 6):101-104, 1995.
24. Hortobagyi GN: Management of breast cancer; Status and future trends. Semin Oncol 22(5, Suppl 12):101-107, 1995.
25. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel activity in heavily pretreated breast cancer; A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13(8):2056-2065, 1995.
26. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin refractory or mitoxantrone-refractory breast cancer; A phase I / I I trial of 96-hour infusion. J Clin Oncol 12(8):1621-1629, 1994. (Pubitemid 24244998)
27. Piccart M J, Gore M, Ten Bokkel Huinink W, et al: Docetaxel; An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87(9):676-681, 1995.
28. Bissery M, Nohynek G, Sanderink G, et al: Docetaxel (Taxotere); A review of preclinical and clinical experience, Part I; Preclinical Experience. Anti-Cancer Drugs 6(3):339-355, 1995.
29. van Oosterom AT, Schriivers D: Docetaxel (Taxotere); A review of preclinical and clinical experience, Part II; Clinical experience. Anti-Cancer Drugs 6:356-368, 1995.
30. Hudis CA, Seidman AD, Crown JP, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14(1):58-65, 1996.
31. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer; A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oneol 14(2):422-428, 1996.
32. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer; A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13(2):314-322, 1995.
33. Eisenhauer EA, Trudeau M: An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Cancer 31A(Suppl 4): 11-13, 1995.
34. Fumoleau P, Chevallier B, Kerbrat P, et al: First line chemotherapy with Taxotere in advanced breast cancer; A phase II study of the EORTC Clinical Screening Group [Abstract]. Proc Am Soc Clin Oneol 12:56 (Abst 27), 1993.
35. Seidman AD, Hudis C, Crown JPA, et al: Phase II evaluation of Taxotere (RP56976, NSC 628503) as initial chemotherapy for metastatic breast cancer EAbstractl. Proc Am Soe Clin Oncol 12:63 (Abst 52), 1993.
36. Trudeau ME, Eisenhauer E, Lofters W, et al: Phase II study of Taxotere as first line chemotherapy for metastatic breast cancer; A National Cancer Institute of Canada Clinical Trials Group study IAbstractl. Proc Am Soc Clin Oncol 12:64 (Abst 59), 1993.
37. Guastalla JP, Bonneterre J, Fumoleau P, et al: A phase II trial of Docetaxel in Patients with anthracycline resistant metastatic breast cancer [Abstract]. 8th European Conference on Clinical Oncology and Cancer Nursing, Paris, 29/10-2/11/95, 1995.
38. Ravdin PM, Burris HA, 3rd, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13(12):2879-2885, 1995.
39. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel; A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13(12):2886-2894, 1995.
40. Priebe W, Perez Soler R: Design and tumor targeting of anthracyclines able to overcome multidrug resistance; A double-advantage approach. Pharmaeol Ther 60(2):215-234, 1993. (Pubitemid 24117376)